Compare BDSX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDSX | CUE |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.0M | 49.6M |
| IPO Year | 2020 | 2018 |
| Metric | BDSX | CUE |
|---|---|---|
| Price | $7.95 | $0.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $32.50 | $3.00 |
| AVG Volume (30 Days) | 63.1K | ★ 249.2K |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $80,173,000.00 | $7,100,000.00 |
| Revenue This Year | $20.75 | $36.58 |
| Revenue Next Year | $25.05 | $32.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.29 | N/A |
| 52 Week Low | $3.44 | $0.47 |
| 52 Week High | $32.20 | $1.75 |
| Indicator | BDSX | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 29.93 |
| Support Level | $7.77 | $0.47 |
| Resistance Level | $8.38 | $0.51 |
| Average True Range (ATR) | 0.57 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 60.38 | 10.78 |
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.